Dyne Therapeutics’ (DYN) Buy Rating Reiterated at Guggenheim

Guggenheim restated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYNFree Report) in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a $50.00 price target on the stock.

Several other brokerages have also issued reports on DYN. Chardan Capital reissued a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a report on Tuesday. Piper Sandler lowered their price objective on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. JPMorgan Chase & Co. reduced their target price on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a report on Friday, March 21st. Robert W. Baird cut their price objective on shares of Dyne Therapeutics from $46.00 to $32.00 and set an “outperform” rating for the company in a report on Wednesday. Finally, BMO Capital Markets began coverage on shares of Dyne Therapeutics in a report on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $43.93.

Read Our Latest Analysis on DYN

Dyne Therapeutics Stock Down 0.7%

DYN opened at $10.78 on Wednesday. The firm has a 50-day simple moving average of $11.46 and a two-hundred day simple moving average of $14.84. Dyne Therapeutics has a 52 week low of $6.36 and a 52 week high of $47.45. The company has a market capitalization of $1.23 billion, a PE ratio of -3.00 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYNGet Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.17). As a group, sell-side analysts expect that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd grew its holdings in Dyne Therapeutics by 378.6% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company’s stock valued at $32,000 after purchasing an additional 2,446 shares during the period. Quarry LP purchased a new stake in Dyne Therapeutics in the first quarter valued at approximately $47,000. GF Fund Management CO. LTD. purchased a new stake in Dyne Therapeutics in the fourth quarter valued at approximately $50,000. E Fund Management Co. Ltd. grew its holdings in Dyne Therapeutics by 16.2% in the first quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company’s stock valued at $144,000 after purchasing an additional 1,923 shares during the period. Finally, Optimize Financial Inc purchased a new stake in Dyne Therapeutics in the first quarter valued at approximately $154,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

See Also

Analyst Recommendations for Dyne Therapeutics (NASDAQ:DYN)

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.